Fig. 5. SC66 increases the sensitivity of mouse xenografts to anticancer drugs.

a A2780/COL11A1 ovarian cancer xenografts treated with only SC66 at doses of 5 mg/kg and 15 mg/kg or combined with 3 mg/kg cisplatin. * P < 0.05, on Day 23, SC66 15 mg/kg + CDDP 3 mg/kg vs. CDDP alone (P = 0.021) or varying doses of SC66 (5 mg/kg, P = 0.021; 15 mg/kg, P = 0.043). b A2780/COL11A1 ovarian cancer xenografts treated with only SC66 at doses of 5 and 15 mg/kg or combined with 12 mg/kg paclitaxel. CDDP: cisplatin; PAC: paclitaxel. Tumor size (mean ± SD): control group 6648.38 ± 2258.12 mm³; 5 mg/kg SC66 group 3883.70 ± 843.91 mm³; 15 mg/kg SC66 group 1006.93 ± 819.18 mm³; CDDP group 2691.58 ± 1756.27 mm³; 5 mg/kg SC66 + 3 mg/kg CDDP group 995.83 ± 519.68 mm³; 15 mg/kg SC66 + 3 mg/kg CDDP group 256.30 ± 90.52 mm³; PAC group 5086.15 ± 2816.66 mm³; 5 mg/kg SC66 + 12 mg/kg PAC group 1143.63 ± 291.24 mm³; 15 mg/kg SC66 + 12 mg/kg PAC group 964.13 ± 853.27 mm³. c Representative IHC photos of p-Akt, Akt, and COL11A1 in ovarian tumor samples from mice treated with SC66 or vehicle controls